Statistics from Altmetric.com
Lemoine et al's excellent article from the Gambia reported on non-invasive markers of liver fibrosis in patients with chronic HBV infection.1 They propose a novel biomarker—the gamma-glutamyl transpeptidase (GGT) to platelet ratio (GPR)—as a routinely available test that could identify patients with fibrosis or cirrhosis in resource-limited settings, thereby informing prognosis and guiding monitoring. Notably, the study excluded patients with conditions that might predispose to altered GGT or platelet counts, including pregnancy, significant alcohol consumption, use of antiviral therapy, acute malaria and hepatitis C, hepatitis delta or HIV coinfection. In their letter, Boyd and colleagues subsequently reported that in a French HBV/HIV coinfected cohort, GPR showed reasonable performance for identifying significant liver fibrosis.2
HBV and HIV are highly co-endemic in West Africa, and chronic liver disease is an emerging threat to the long-term health of HIV-positive patients in this region.3 Since 2010, we have been following a prospective cohort of patients attending the HIV clinic at the Komfo Anokye Teaching Hospital in Kumasi, Ghana, where prevalence of HBV co-infection is 14% (95% CI 12.4% to 15.8%).4 To date, 122 patients have undergone laboratory investigations paired with a valid measurement of liver fibrosis by transient elastography (TE) (Fibroscan F402, Echosens, Paris). Here, we report on the performance of the GPR and AST to platelet ratio index (APRI) in this cohort, in relation to TE measurements as a reference standard. Interpretive cut-offs were 7.6 kPa (F3: advanced fibrosis) and 9.4 kPa (F4: cirrhosis) as previously determined for HBV/HIV coinfection.4
For the purpose of the analysis, we excluded patients with pregnancy (n=2), significant alcohol consumption (n=1), acute malaria (n=2) and detectable HCV RNA (n=0) or hepatitis delta virus (HDV) RNA (n=1). In order to reflect the currently predominant profile of HIV-positive patients across sub-Saharan Africa, we only included patients established on antiretroviral therapy (ART) with two nucleoside/nucleotide reverse transcriptase inhibitors plus efavirenz (n=89) or nevirapine (n=11), and excluded those not receiving ART (n=6) or receiving protease inhibitors (n=10).
The 100 patients (67% female) were median 44 years old (IQR 38–48), had received ART for median 7.2 years (5.0–9.0) and had a CD4 count of median 572 cells/mm3 (361–711); 78% showed plasma HIV-1 RNA suppression (<40 copies/mL). Median AST, GGT and platelet counts were 32 U/L (25–39), 60 U/L (44–81) and 165×109/L (118–225), respectively. TE measurements were median 4.6 kPa (3.8–6.2). Of 100 patients, 18% and 7% were classified as having advanced fibrosis and cirrhosis, respectively. Factors significantly associated with TE measurements were GGT (r=0.33, p=0.001), AST (r=0.34, p=0.001), CD4 count (r=−0.21, p=0.033), APRI (r=0.24, p=0.014), GPR (r=0.29, p=0.004) (Spearman's r) and male gender (p=0.013, Mann–Whitney) (figure 1); there was no correlation with duration of ART (p=0.99) or age (p=0.76).
GPR and APRI had good negative predictive values for excluding cirrhosis (96%) and, to a lesser extent, advanced fibrosis (89% and 90%, respectively) (table 1). Overall diagnostic performance was poor for identifying advanced fibrosis and cirrhosis, however, with positive predictive values of 32% and 17% for GPR, and 29% and 14% for APRI. GPR had a better diagnostic performance than APRI for advanced fibrosis but not for cirrhosis (p=0.029 and 0.13, respectively, DeLong). It is important to note that the APRI threshold for the diagnosis of cirrhosis (>2.0) recommended by the WHO was unsuitable in this population, such that none of the seven patients with cirrhosis were correctly identified.3
The non-invasive and routinely available biomarkers GPR and APRI cannot be recommended for the diagnosis of advanced fibrosis and cirrhosis in HIV/HBV coinfected population established on ART in West Africa due to insufficient positive predictive value.
Collaborators Lambert Tetteh Appiah; Alessandra Ruggiero; Giovanni Villa; David Chadwick; Sanjay Bhagani; Laura Bonnett; Fred Stephen Sarfo; Geoff Dusheiko; Dorcas Owusu; Apostolos Beloukas; Ian Harrison; Geraldine Foster; Colette Smith; John Ambrose; Kwabena Adjei-Asante; Simon King.
Contributors AJS collected the data, performed the statistical analysis and wrote the manuscript. ROP designed the study and assisted with data collection.AMG designed the study, contributed to data collection and analysis, and reviewed and revised the manuscript.
Funding This study was supported by a Leverhulme- Royal Society Africa award. An award made by the MAC AIDS Foundation to the Royal Free Charity supported insured transport to Ghana of the portable fibroscan. AJS is supported by a Wellcome Trust Clinical PhD Fellowship.
Disclaimer The funders had no role in the collection, analysis and interpretation of the data, the writing of the report and in the decision to submit this data for publication.
Competing interests None declared.
Ethics approval Ethics Board of the Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Provenance and peer review Not commissioned; internally peer reviewed.
Data sharing statement For information on additional unpublished data, contact Dr Alexander Stockdale (email@example.com).
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.